Women undergoing mastectomy for breast cancer who had low vitamin D levels before surgery were roughly three times more likely to experience moderate-to-severe pain in the first 24 hours, according to a prospective observational study of 184 patients at Fayoum University Hospital in Egypt. The research, which recruited patients between September 2024 and April 2025, found an adjusted odds ratio of approximately 3.12 linking vitamin D deficiency to worse acute pain outcomes, even when patients received standard paracetamol and patient-controlled analgesia (PCA) tramadol. The finding raises a direct question for surgical teams: whether correcting a cheap, measurable deficiency before the operating room could spare patients significant suffering.
Why preoperative vitamin D screening matters for mastectomy patients
Breast cancer surgery already carries a well-documented risk of persistent pain, and the first 24 postoperative hours often set the trajectory. The Fayoum University Hospital team measured serum 25(OH)D levels before each operation and defined deficiency as a reading below 30 nmol/L. Women who fell under that threshold reported significantly worse pain scores during the immediate recovery window, a result that held after the researchers adjusted for other variables. The adjusted odds ratio of approximately 3.12 means deficient patients faced more than triple the likelihood of moderate-to-severe pain compared with those whose levels were adequate.
The practical tension is straightforward. Many cancer centers already check vitamin D as part of routine bloodwork, yet few act on the result before scheduling surgery. Vitamin D supplementation is inexpensive and widely available. If the association reported in this study reflects a causal relationship, then a short course of supplementation could reduce acute pain and, potentially, the volume of analgesics consumed in the hours after a mastectomy. That possibility leads to a testable hypothesis: preoperative correction of vitamin D to above 50 nmol/L in deficient patients would produce a measurable drop in 24-hour PCA tramadol consumption that exceeds the effect size observed in this and similar observational data, independent of baseline anxiety scores. No trial has yet tested that proposition in mastectomy patients.
Converging surgical evidence beyond breast cancer
The Fayoum findings do not stand alone. A separate peer-reviewed study examining patients who underwent laparoscopic cholecystectomy found that vitamin D status correlated with both postoperative pain intensity and opioid analgesic consumption. That study used a similar perioperative pain-scoring methodology and tracked opioid use as a concrete outcome measure, giving it a parallel design logic to the mastectomy research.
A retrospective cohort study in patients who had video-assisted thoracoscopic surgery reported a comparable association between low preoperative vitamin D and moderate-to-severe acute pain. The investigators in that study also discussed possible inflammatory mediator pathways, suggesting that vitamin D deficiency may amplify the body’s pain-signaling response to tissue injury. A broader systematic review of vitamin D status and surgical outcomes across diverse procedures noted similar patterns but flagged mixed results overall, with some surgery types showing weaker or inconsistent links.
Taken together, the signal appears across at least three distinct surgical populations: breast, abdominal, and thoracic. The consistency of the direction, if not always the magnitude, strengthens the case that preoperative vitamin D status is more than a bystander marker. Still, consistency across observational studies does not prove causation. Each of these studies measured an association, and none randomly assigned patients to receive supplementation before surgery.
Gaps in the mastectomy pain data and what to watch next
Several limits in the current evidence deserve attention. The Fayoum study enrolled 184 women, all undergoing unilateral modified radical mastectomy at a single center. That sample size is large enough to detect a strong association but too small to capture rarer complications or to stratify results by tumor stage, body mass index, or concurrent chemotherapy. The registered trial protocol specified 25(OH)D measurement and a deficiency threshold of below 30 nmol/L, along with the paracetamol and PCA tramadol analgesia plan, but it did not include collection of inflammatory cytokine levels or other mechanistic biomarkers. Without those data, the biological pathway connecting low vitamin D to heightened pain remains inferred from other surgical populations rather than demonstrated in this cohort.
The study also tracked pain only during the first 24 hours. Chronic post-mastectomy pain, which affects a substantial fraction of breast cancer survivors, was not part of the registered outcomes. Whether preoperative vitamin D status predicts pain weeks or months later is an open question that this dataset cannot answer.
No direct statements from study participants or operating surgeons about perceived pain differences appear in the published record. The evidence rests entirely on aggregate odds ratios and pain-scale scores, which, while standard in clinical research, leave out the lived experience that might sharpen clinical urgency.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
